FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
Pharma Solutions operates 10 research and development and/or production sites globally
Subscribe To Our Newsletter & Stay Updated